The estimated Net Worth of Diego Cadavid is at least $707 Tisíc dollars as of 11 February 2022. Diego Cadavid owns over 928 units of Fulcrum Therapeutics Inc stock worth over $62,897 and over the last 5 years he sold FULC stock worth over $93,983. In addition, he makes $550,364 as Senior Vice President - Clinical Development at Fulcrum Therapeutics Inc.
Diego has made over 10 trades of the Fulcrum Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 928 units of FULC stock worth $8,213 on 11 February 2022.
The largest trade he's ever made was selling 2,143 units of Fulcrum Therapeutics Inc stock on 2 March 2020 worth over $37,245. On average, Diego trades about 791 units every 49 days since 2019. As of 11 February 2022 he still owns at least 7,107 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Diego Cadavid stock trades at the bottom of the page.
Dr. Diego Cadavid serves as Senior Vice President - Clinical Development of the Company. Dr. Cadavid currently serves as an adjunct professor at the University of Massachusetts Medical School. Dr. Cadavid previously served as senior medical director in the M.S Clinical Development Group at Biogen Inc., or Biogen, a biotechnology company, from January 2014 to September 2016 and as a director of the Neurology Clinical Group at Biogen from April 2008 to December 2013. Before joining Biogen, Dr. Cadavid spent nine years at Rutgers-New Jersey Medical School where he was Associate Professor of Neurology and Neuroscience. While working at Biogen, Dr. Cadavid served as a consultant at the Center for Immunology and Inflammatory Diseases at the Massachusetts General Hospital in Boston. Dr. Cadavid received an M.D. from Pontificia Universidad Javeriana in Bogota, Colombia.
As the Senior Vice President - Clinical Development of Fulcrum Therapeutics Inc, the total compensation of Diego Cadavid at Fulcrum Therapeutics Inc is $550,364. There are 5 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.
Diego Cadavid is 54, he's been the Senior Vice President - Clinical Development of Fulcrum Therapeutics Inc since 2018. There are 8 older and 5 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
Diego's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk a Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: